Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics Plc LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.75 -3.12% 23.25 457,984 12:46:55
Bid Price Offer Price High Price Low Price Open Price
23.00 23.50 24.00 23.25 24.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 78.20 8.07 1.11 20.9 149
Last Trade Time Trade Type Trade Size Trade Price Currency
16:32:20 O 50,000 23.50 GBX

Allergy Therapeutics (AGY) Latest News (2)

More Allergy Therapeutics News
Allergy Therapeutics Investors    Allergy Therapeutics Takeover Rumours

Allergy Therapeutics (AGY) Discussions and Chat

Allergy Therapeutics Forums and Chat

Date Time Title Posts
16/4/202113:57Allergy Therapeutics - AGY -4,067
14/7/201621:04Mike Mitchell Panmure Gordon who covers Allergy Therapeutics PLC (LON:AGY)1
16/12/201510:24Allergy Therapeutics-Transforming Allergy Treatment26
03/2/201213:58Ready to ROCKET?-
04/12/200512:00AGY - Allergy Therapeutics79

Add a New Thread

Allergy Therapeutics (AGY) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-04-16 15:32:2123.5050,00011,750.00O
2021-04-16 15:22:5623.3760,80014,208.96O
2021-04-16 14:48:4723.355,0001,167.50O
2021-04-16 14:46:0223.0010,0002,300.00O
2021-04-16 13:05:0323.011,604369.00O
View all Allergy Therapeutics trades in real-time

Allergy Therapeutics (AGY) Top Chat Posts

Allergy Therapeutics Daily Update: Allergy Therapeutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AGY. The last closing price for Allergy Therapeutics was 24p.
Allergy Therapeutics Plc has a 4 week average price of 20.25p and a 12 week average price of 18.20p.
The 1 year high share price is 25p while the 1 year low share price is currently 10.38p.
There are currently 640,792,164 shares in issue and the average daily traded volume is 274,828 shares. The market capitalisation of Allergy Therapeutics Plc is £148,984,178.13.
jimmyloser: Kev I am with you on that. People ignore at their peril the wide portfolio that they have coming through. Peanuts will bring worldwide attention because it is an area that the media will love and the publicity will do the share price no harm. This is a remarkable business and on the proviso that AGY do not have any further setbacks then peeps patience will be rewarded beyond any current expectations Impo
kevraff: Long road to go guys AGY only getting started
sev22: jimmyloser, regardless of how long Spring is AGY looks way undervalued. This is an extract from the last House broker's note: 'Given the balance sheet (£48.3m cash), which is sufficient to fully fund its core R&D projects, we believe the risk/reward profile is highly attractive and reiterate our 45p target price, pointing out the substantial and unwarranted discount to its nearest peer (ALK-abello - 6.9x EV/Sales). This target also excludes the value of US market entry via the Grass MATA MPL vaccine (c.12-17p) or VLP Peanut allergy vaccine (c.5-10p).'
jimmyloser: You may recall that on December 23rd 2020 our share price and Futura Medicals were both trading neck and neck in low teens and I posted this................. 23 Dec '20 - 08:15 - 3945 of 4049 Edit As we approach the rag end of another trading year, I note that both AGY and FUM are trading at exactly the same price this morning. Both appear to hold products in their portfolio's that could well be a game changer in 2021. Perhap's this is harsh, but AGY seem to be permanently in the 'could' phase whilst FUM have time on their hands. I currently do not hold FUM, but for fun will buy some. Let's see where both are at, come the end of March! dyor/impo Now it is the end of March, three months and both have made progress. AGY now trading at 20/21p and Futura trading at 54p/56p as I type. They touched 80p! What a difference 13 weeks makes! I also said that I would buy some for fun. I didn't! dyor/impo
jimmyloser: Page 7 of to-days Sunday Times ISA Supplement will make both interesting and exciting reading for many I suspect and particulary when linked with appearances such as the HC Wainright Conference. They (AGY) have gone 'loud' impo, and one doesn't do that unless one is confident and especially about the peanut trials. Eyes are on us, that's for sure :-) all impo/dyor
jimmyloser: I am not sure if this is accurate in this case - please do your own research Definition of 'Share Pledge' Definition: Pledging of shares is one of the options that the promoters of companies use to secure loans to meet working capital requirement, personal needs and fund other ventures or acquisitions. A promoter shareholding in a company is used as collateral to avail a loan. While pledging shares, promoters retain their ownership. However, as the share price keeps fluctuating, the value of the collateral also changes. When the value of the shares pledged with a lender falls below a certain level, it triggers ‘margin call’, requiring the promoters to make up for the shortfall in the value of the collateral. Description: Share pledge can be troublesome for companies at times, as promoters are required to maintain the value of the collateral all the time by providing additional shares to lenders when their value erodes. In case promoters fail to make up for the difference, lenders can sell the shares in the open market to recover the money. This can lead to a reduction in the promoters’ shareholding in the company, further value erosion in the stock due to infusion of additional paper in the market, and even sudden change of guard in the company because of alteration in shareholding pattern.
jimmyloser: This deck was posted earlier today by SEV22. (Brilliant SEV22 and thanks) I have been in AGY for more years than I care to remember and impo, this is by far the most clear case that have ever posted. impo, do view it yourself SEV22 10 Mar '21 - 07:58 - 4036 of 4043 0 0 0 A new presentation has appeared on AGY's web-site titled 'Delivering on our Strategy' (2021).
jimmyloser: Remember this? It should make interesting reading 23 Dec '20 - 08:15 - 3945 of 4025 Edit 0 1 0 As we approach the rag end of another trading year, I note that both AGY and FUM are trading at exactly the same price this morning. Both appear to hold products in their portfolio's that could well be a game changer in 2021. Perhap's this is harsh, but AGY seem to be permanently in the 'could' phase whilst FUM have time on their hands. I currently do not hold FUM, but for fun will buy some. Let's see where both are at, come the end of March! dyor/impo
wizzkid211: Allergy Therapeutics PLC Initiation of peanut allergy biomarker study January 05 2021 - 02:00AM UK Regulatory (RNS & others) Alert Print Share On Facebook TIDMAGY RNS Number : 5198K Allergy Therapeutics PLC 05 January 2021 Allergy Therapeutics plc ("Allergy Therapeutics", "ATL" or the "Group") Allergy Therapeutics initiates peanut allergy biomarker study with Imperial College London to confirm potential of novel peanut vaccine candidate - Ex-vivo biomarker study to evaluate VLP-based peanut allergy vaccine candidate's hypoallergic potential and potent immune response - Findings to support peanut clinical programme with first-in-human trial on track for 2021 - Short-course vaccine candidate represents significant differentiated opportunity in $8bn worldwide food allergy market - IND application to United States Food and Drug Administration expected in 2021 5 January 2021 Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announces that an ex-vivo biomarker study of blood samples from peanut allergy patients has begun at Imperial College London. The study aims to evaluate the Group's novel virus like particle (VLP) based peanut allergy vaccine candidate, to confirm its hypoallergic potential and its potent immune response. The study at Imperial College London, using human samples and an extensive set of functional and molecular biomarkers, will provide Allergy Therapeutics with important information to establish the starting dose for its first-in-human Phase I study. The data will also act as an early clinical predictor of efficacy of the VLP platform and support the acceptance of the Investigational New Drug (IND) application and a successful Phase I trial outcome. The submission of an IND application to the United States Food and Drug Administration (FDA) for that study is expected in 2021. Allergy Therapeutic's peanut allergy vaccine programme is supported by a strong preclinical research package, providing pre-clinical proof of concept for sustained immunity and protection against peanut anaphylaxis after a single vaccination. Importantly, in contrast to current treatment approaches such as desensitisation via oral administration or transdermal patches, which require daily dosing over several years, it is anticipated that the Group's next-generation VLP-based peanut vaccine candidate will use only 3 injections to induce sustained protection. The potential of an effective short-course peanut allergy vaccine represents a significant opportunity in the $8 billion worldwide food allergy market(1) . Prevalence of peanut allergy in Western countries is on the rise and currently ranges from 1.4-3% of children(2) and, in the US, peanut allergy affects an estimated 1.2% of the overall US population(3) with 1 in 4 children with a peanut allergy requiring a hospital visit each year(4) . In parallel with the peanut allergy human biomarker study, a broader research project with Imperial College London has also commenced, focussing on the selection, measurement and analysis of pre-clinical and clinical biomarkers for allergen immunotherapy products across Allergy Therapeutics' portfolio. Clinical trials in the allergy immunotherapy area often pose challenges with interpretation as they rely on subjective non-validated endpoints. There is therefore an opportunity to explore alternative, more objective measures of success and develop a greater understanding of the underlying science in this important area. Under this collaboration agreement, researchers will examine samples from the Group's ongoing Grass MATA MPL exploratory field study (G309), and the pre-clinical and clinical development programme for the Group's VLP-based peanut allergy vaccine candidate. Changes in an extensive set of established and innovative biomarkers will be analysed at baseline and throughout treatment with each of the allergen immunotherapies. Manuel Llobet, CEO of Allergy Therapeutics , stated: "A safe and effective short-course peanut allergy vaccine would be a significant breakthrough product, offering life-changing benefits to sufferers affected by this condition. The data we have generated so far for our peanut vaccine candidate give us confidence in its potential and through this study we have an opportunity to build on that confidence and provide our upcoming Phase I study with the greatest chances of success. "At Allergy Therapeutics we are passionate about progressing the science around allergy immunotherapies. Our collaboration with Imperial College London, who are one of the foremost experts in this field, will equip us with a greater depth of knowledge of allergy biomarkers and their relationship to clinical outcomes, which will be applied to future clinical trials and aid in the development of our allergy immunotherapy pipeline."
jimmyloser: This is indeed good to see, I guess it was a case of the share price being over hammered. The management did what they had to in cases like this and just got on with making sure that the business delivered. They and we have been through a very tough time, but patience and belief will be and is being rewarded. Considering the box of tricks that they have up their sleeves, this lowly share price remains a mystery to me.............but for how long? (Yes, I have been buying solidly) dyor/impo
Allergy Therapeutics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Allergy Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210417 09:12:43